SE0002202D0 - New peptides - Google Patents

New peptides

Info

Publication number
SE0002202D0
SE0002202D0 SE0002202A SE0002202A SE0002202D0 SE 0002202 D0 SE0002202 D0 SE 0002202D0 SE 0002202 A SE0002202 A SE 0002202A SE 0002202 A SE0002202 A SE 0002202A SE 0002202 D0 SE0002202 D0 SE 0002202D0
Authority
SE
Sweden
Prior art keywords
new peptides
alkylating
invention refers
peptides
new
Prior art date
Application number
SE0002202A
Other languages
English (en)
Swedish (sv)
Inventor
Rolf Lewensohn
Joakim Gullbo
Rolf Larsson
Hans Ehrsson
Kristina Luthman
Original Assignee
Karolinska Innovations Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karolinska Innovations Ab filed Critical Karolinska Innovations Ab
Priority to SE0002202A priority Critical patent/SE0002202D0/xx
Publication of SE0002202D0 publication Critical patent/SE0002202D0/xx
Priority to CA2408501A priority patent/CA2408501C/en
Priority to US10/297,588 priority patent/US6992207B2/en
Priority to DK01938945.1T priority patent/DK1290011T3/da
Priority to JP2002510508A priority patent/JP4798930B2/ja
Priority to AU2001264515A priority patent/AU2001264515A1/en
Priority to DE60141398T priority patent/DE60141398D1/de
Priority to PCT/SE2001/001318 priority patent/WO2001096367A1/en
Priority to PT01938945T priority patent/PT1290011E/pt
Priority to EP01938945A priority patent/EP1290011B1/en
Priority to AT01938945T priority patent/ATE458746T1/de
Priority to ES01938945T priority patent/ES2341702T3/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0002202A 2000-06-13 2000-06-13 New peptides SE0002202D0 (sv)

Priority Applications (12)

Application Number Priority Date Filing Date Title
SE0002202A SE0002202D0 (sv) 2000-06-13 2000-06-13 New peptides
ES01938945T ES2341702T3 (es) 2000-06-13 2001-06-11 Derivados de melfalan y su uso como farmacos quimioterapeuticos del cancer.
JP2002510508A JP4798930B2 (ja) 2000-06-13 2001-06-11 メルファラン誘導体及び癌の化学療法薬としてのその使用
US10/297,588 US6992207B2 (en) 2000-06-13 2001-06-11 Melphalan derivatives and their use as cancer chemotherapeutic drugs
DK01938945.1T DK1290011T3 (da) 2000-06-13 2001-06-11 Melphalan-derivater og deres anvendelse som cancer-kemoterapeutiske lægemidler
CA2408501A CA2408501C (en) 2000-06-13 2001-06-11 Melphalan derivatives and their use as cancer chemotherapeutic drugs
AU2001264515A AU2001264515A1 (en) 2000-06-13 2001-06-11 Melphalan derivatives and their use as cancer chemotherapeutic drugs
DE60141398T DE60141398D1 (de) 2000-06-13 2001-06-11 Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs
PCT/SE2001/001318 WO2001096367A1 (en) 2000-06-13 2001-06-11 Melphalan derivatives and their use as cancer chemotherapeutic drugs
PT01938945T PT1290011E (pt) 2000-06-13 2001-06-11 Derivados de melfalano e seu uso como drogas quimioterapêuticas de cancro
EP01938945A EP1290011B1 (en) 2000-06-13 2001-06-11 Melphalan derivatives and their use as cancer chemotherapeutic drugs
AT01938945T ATE458746T1 (de) 2000-06-13 2001-06-11 Melphalan-derivate und ihre verwendung als chemotherapeutika gegen krebs

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002202A SE0002202D0 (sv) 2000-06-13 2000-06-13 New peptides

Publications (1)

Publication Number Publication Date
SE0002202D0 true SE0002202D0 (sv) 2000-06-13

Family

ID=20280067

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002202A SE0002202D0 (sv) 2000-06-13 2000-06-13 New peptides

Country Status (10)

Country Link
EP (1) EP1290011B1 (OSRAM)
JP (1) JP4798930B2 (OSRAM)
AT (1) ATE458746T1 (OSRAM)
AU (1) AU2001264515A1 (OSRAM)
CA (1) CA2408501C (OSRAM)
DK (1) DK1290011T3 (OSRAM)
ES (1) ES2341702T3 (OSRAM)
PT (1) PT1290011E (OSRAM)
SE (1) SE0002202D0 (OSRAM)
WO (1) WO2001096367A1 (OSRAM)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1374907A3 (en) * 2002-06-24 2004-01-07 Ghanem Elias c/o Institut Jules Bordet Ghanem Drug transport and delivery system
DE10239832A1 (de) * 2002-08-29 2004-03-18 Lipal Biochemicals AG c/o University of Zurich Sarcolysyl-Derivate und Verfahren zu deren Herstellung
WO2011011865A1 (en) * 2009-07-29 2011-02-03 3R Valo, S.E.C. Anticancer agents based on amino acid derivatives
WO2011078782A1 (en) * 2009-12-22 2011-06-30 Oncopeptides Ab A composition comprising of melphalan derivatives and gemcitabine or etoposide useful in the treatment of cancer
ES2930140T3 (es) 2011-04-28 2022-12-07 Oncopeptides Ab Preparación liofilizada de dipéptidos citotóxicos
PT3228319T (pt) * 2011-04-28 2020-08-27 Oncopeptides Ab Preparação liofilizada de dipéptidos citotóxicos
HUE047813T2 (hu) * 2012-10-26 2020-05-28 Oncopeptides Ab Melphalan-flufenamidot tartalmazó liofilizált készítmények
SMT202000058T1 (it) * 2012-10-26 2020-03-13 Oncopeptides Ab Preparazioni liofilizzate di melfalan flufenammide
GB201507903D0 (en) * 2015-05-08 2015-06-24 Oncopeptides Ab Process for preparation of nitrogen mustard derivatives
GB201521217D0 (en) 2015-12-01 2016-01-13 Oncopeptides Ab Dosage regimens
CN108864251B (zh) * 2018-06-30 2022-06-14 大连理工大学 一类氨肽酶n激活的药物前体化合物及其制备方法和应用
CA3116198A1 (en) * 2018-10-18 2020-04-23 Oncopeptides Ab Compounds containing deuterium
EP3946309A1 (en) 2019-04-03 2022-02-09 Oncopeptides AB Treatment of al amyloidosis with melflufen
GB201905477D0 (en) 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
WO2022167087A1 (en) * 2021-02-05 2022-08-11 Oncopeptides Ab Peptidase enhanced cytotoxic dipeptides
EP4083052A1 (en) 2021-04-29 2022-11-02 BKmdcl AB Peptide conjugates of melphalan for the treatment of cancer
US20240270680A1 (en) 2021-06-01 2024-08-15 Synthon B.V. Process for making melflufen or a salt thereof
GB202109896D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109894D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
GB202109895D0 (en) 2021-07-08 2021-08-25 Oncopeptides Ab Novel treatments
JP2024524552A (ja) 2021-07-08 2024-07-05 オンコペプティデス エービー 多発性骨髄腫の治療に使用するためのメルフルフェン
GB202204171D0 (en) 2022-03-24 2022-05-11 Oncopeptides Ab Novel formulations

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB750155A (en) 1953-03-17 1956-06-13 Nat Res Dev Substituted alanines

Also Published As

Publication number Publication date
ATE458746T1 (de) 2010-03-15
PT1290011E (pt) 2010-05-11
ES2341702T3 (es) 2010-06-25
AU2001264515A1 (en) 2001-12-24
JP4798930B2 (ja) 2011-10-19
JP2004503564A (ja) 2004-02-05
CA2408501A1 (en) 2001-12-20
EP1290011A1 (en) 2003-03-12
DK1290011T3 (da) 2010-06-07
CA2408501C (en) 2011-01-18
EP1290011B1 (en) 2010-02-24
WO2001096367A1 (en) 2001-12-20

Similar Documents

Publication Publication Date Title
SE0002202D0 (sv) New peptides
BR9713404A (pt) ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos.
DK1178958T3 (da) N-cyanomethylamider som proteaseinhibitorer
DZ3197A1 (fr) Acides aminés bicycliques utilises comme agents pharmaceutiques.
NZ593815A (en) Tissue factor pathway inhibitor (tfpi) inhibitors and methods of use
BR9714358A (pt) Derivados de n- (arila/heteroarila) amino ácido,composições farmacêuticas compreendendo os mesmos, e métodos para a inibição de liberação de peptìdeo beta-amilóide e/ou sua sìntese por uso de tais compostos
WO2004091497A3 (en) Methods and compositions for increasing the anaerobic working capacity in tissues
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
WO2001068645A3 (en) N-cyanomethylcarboxamides and their use as protease inhibitors
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
WO2002062304A3 (de) Kosmetische und/oder pharmazeutische mittel acylierte aminosäure und proteinkondensat enthaltend.
NO955067D0 (no) FVII/TF peptider
WO2005002500A3 (en) Inhibitors of coronavirus
EE200300213A (et) SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks
BR0109279A (pt) Antagonistas de lhrh, sua preparação e aplicação como medicamento
DE50113974D1 (de) Kombinationspräparate von 3-n-formylhydroxylaminopropylphosphonsäurederivaten oder 3-n-acetylhydroxylaminopropylphosphonsäurederivaten mit speziellen pharmazeutischen wirkstoffen
ATE371737T1 (de) Proteaseresistente flint-analoge
BR9811954A (pt) ácidos 3-aril-succinamido-hidroxâmicos, processos para sua produção e preparações farmacêuticas contendo estas substâncias
IT1318556B1 (it) Composizione farmaceutica a base di prolina, glicina e lisina utilenella terapia per la cicatrizzazione delle ferite e delle lesioni
MXPA02001268A (es) Antagonistas de il-16.
EP1774966A4 (en) MEANS TO INHIBIT THE USE AND PROGRESS OF LIVER CANCER IN PATIENTS WITH HEPATITIS C-VIRUS POSITIVE LIVER CIRR
WO2003025014A3 (fr) Utilisation de peptides comportant des modifications de type post-traductionnel dans le cadre du traitement de pathologies auto-immunes
DE60015559D1 (de) Sentrin-spezifische menschliche protease senp1
DE60137340D1 (de) Inhibitoren von hiv-replikation und verfahren zur behandlung einer der von hiv verursachten infektionen